Rigel Pharmaceuticals Inc
RIGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001034842
No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $640.6M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $837.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 157
- 13F valueReported value at the end of Q2 2026
- $640.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $294.3M
- +64.1% year over year
- Net income, FY2025
- $367.0M
- +1,999.1% year over year
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $80.9M
- +16.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.54M
- Shares sold short
- Change
- −197.1K
- −7.2% vs. previous
- Days to cover
- 12.93
- At average daily volume
Superinvestors holding RIGL, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding RIGL at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Rigel Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Ali-Jackson KamilDirector | SSale | −2.50K | $35.00 | −$87.5K | −19.8%10.1K after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Ali-Jackson KamilDirector | SSale | −2.50K | $29.17 | −$72.9K | −16.5%12.6K after | 10b5-1 |
| Feb 24, 2026 (view filing) | Feb 20 | 4 days | Moos Walter HDirector | SSale | −4.00K | $36.36 | −$145.4K | −23.9%12.7K after | |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Schorno Dean LEVP & Chief Financial Officer | SSale | −3.77K | $21.38 | −$80.6K | −6.2%57.2K after | 2 lots |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Santos David AEVP, Chief Commercial Officer | SSale | −3.92K | $21.38 | −$83.8K | −7.0%51.7K after | 2 lots |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Rodriguez Raul RCEO, President | SSale | −9.35K | $21.40 | −$200.1K | −3.8%239.5K after | 2 lots |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Furey Raymond J.EVP, GC, CCO & Corp Sec | SSale | −2.79K | $21.41 | −$59.7K | −6.7%38.8K after | 2 lots |
| Feb 6, 2024 (view filing) | Feb 2-5 | 4 days | Santos David AEVP, Chief Commercial Officer | SSale | −14.5K | $1.14 | −$16.5K | −4.0%349.1K after | 2 lots |
| Feb 6, 2024 (view filing) | Feb 2-5 | 4 days | Schorno Dean LEVP & Chief Financial Officer | SSale | −12.6K | $1.14 | −$14.3K | −3.0%402.9K after | 2 lots |
| Feb 6, 2024 (view filing) | Feb 2-5 | 4 days | Rodriguez Raul RCEO, President | SSale | −52.9K | $1.14 | −$60.1K | −2.5%2.04M after | 2 lots |
Top 10 13F holders, Q2 2026
See all 157 holdersThe largest institutional positions in Rigel Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,939,818 | $75.9M | 0.00% | +170,911+9.7% | Added |
| Soleus Capital Management, L.P. | 1,843,504 | $72.1M | 2.49% | +1,833,504+18,335.0% | Added |
| Armistice Capital, LLC | 1,672,000 | $65.4M | 1.81% | +392,000+30.6% | Added |
| State Street Corp | 1,039,994 | $40.7M | 0.00% | −80,244−7.2% | Reduced |
| Vanguard Capital Management LLC | 785,107 | $30.7M | 0.00% | +20,914+2.7% | Added |
| American Century Companies Inc | 741,718 | $29.0M | 0.01% | +197,287+36.2% | Added |
| LSV Asset Management | 721,666 | $28.2M | 0.05% | +120,159+20.0% | Added |
| Acadian Asset Management LLC | 591,686 | $23.1M | 0.03% | −74,740−11.2% | Reduced |
| D. E. Shaw & Co., Inc. | 542,539 | $21.2M | 0.01% | +96,861+21.7% | Added |
| Geode Capital Management, LLC | 483,175 | $18.9M | 0.00% | +42,549+9.7% | Added |
Holders of 5% or more of RIGL
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Rigel Pharmaceuticals Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 13G/A | 9.90%1.84M shares | +4.70 ppfrom 5.20% | Feb 22, 20237 filings | Aug 13, 2026 | SEC |
| Armistice Capital, LLC | 13G/A | 8.95%1.67M shares | +2.02 ppfrom 6.93% | Feb 14, 20237 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.70%1.38M shares | −2.20 ppfrom 9.90% | Feb 5, 20252 filings | Apr 17, 2025 | SEC |